Successful Control of External Biliary Fistula by Using SMS 201-995 in a Child by Bakhotmah, Mohamad Abid
HPB Surgery, 1996, Vol.9, pp.183-184
Reprints available directly from the publisher
Photocopying permitted by license only
(C) 1996 (OPA (Overseas Publishers Association)
Amsterdam B.V. Published in The Netherlands
by Harwood Academic Publishers GmbH
Printed in Malaysia
CASE REPORT
Successful Control of External Biliary Fistula
by Using SMS 201-995 in a Child
MOHAMAD ABID BAKHOTMAH
Consultant Hepatobiliary Surgeon and Assistant Professor
(Received23 October 1993)
Somatostatin is a potent inhibitory hormone, it’s synthetic analogue is more potent and has a prolonged
action. It has a wide range ofactions in the gastrointestinal system; among which is an anticholeritic action
on bile secretion.
The use of Sandostatin in the management of a case of complicated biliary fistula is reported; it
controlled the fistula reducing its daily output from 200 ml to less than 5 ml per day.
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CASE REPORT
A 4-year old boy was referred to our hospital with
abdominal distention and failure to thrive since he was
3 years old. Liver biopsy was done at the referring
hospital which was in conclusive. On examination,
there was a cystic mass occupying the Right side ofthe
abdomen causing the distention, there was no ascites;
ultrasonography, CT scan, HIDA scan suggested the
diagnosis of Caroli’s disease because of the bilateral
intrahepatic saccular dilatation ofthe biliary tree. The
abdominal CT and ultrasonography demonstrated
the presence of a large cystic mass in the sub-hepatic
region extending to the pelvic inlet but its origin could
not be identified.
At laparotomy three communicating cystic masses
were found in the Right side of abdomen inferior to
the liver and full of bile, but not communicating with
the extra-hepatic biliary tree which looked quite nor-
mal. The cysts were excised after dissecting them from
the inferior surface of the right lobe. The dissection
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was not difficult. A definitive communication between
the liver surface and the cystic mass could not be
identified during surgery but of course, this does not
exclude it’s presence.
A small butterfly needle, was inserted into the
CBD to perform cholangiography, which showed
3 filling defects. The stones were removed through
a choledochotomy and a T-tube was inserted.
The gallbladder was not removed and no biliary
enteric anastomosis performed. Postoperatively, the
histology report of the excised cysts was that it was
typical of Caroli’s disease.
The T-tube cholangiography showed no evidence
of stones in the CBD and contrast was seen in the
duodenum. When, the T-tube was removed the tract
persisted as a biliary fistula which was resistant to any
attempt to close it including cholecystojujenostomy;
done as a 2nd operation, the output was 150-200 mls.
per day and that was for almost 12 months. During
the late course of his illness, the child developed
generalized psoriatic skin-lesions which was then
diagnosed as due to histocystosis-X. Bone marrow
examination confirmed that the disease had spread
to bone marrow. Treatment for histocystosis-X by
cytotoxic therapy was given but it had no effect on
the fistula.
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The child started on Sandostatin 10 tgm 6 hourly
subcutaneously. Within less than 48 hours, the fistula
output markedly reduced to less than 5 mls. per day.
No collection bag was needed only a gauze dressing.
The patient was on Sandostatin for more than one
year before he died due to extensive spread of
histocystosis-X.
DISCUSSION
Sandostatin (SMS 201-995) is the synthetic analogue
ofthe naturally occurring peptide Somatostatin. It has
the same action as Somatostatin but is more potent
and has a prolonged action.
It’s effect on bile secretion has been studied in
several experimental models, it reduces bile secretion
in rats(1) and has an anticholeretic effect in dogs(z).
In man, Somatostatin reduces the bile secretion by
30-40%, it acts on the bile acid-dependent canalicular
bile secretion and also on the bile acid-independent
ductular secretion(3) SMS-201-995 almost abolishes
the cholecystokinin release and gallbladder contrac-
tion(4).
Inspite of such evidences in animal and normal
humans, there is only one case report of using
-..(5). Sandostatin in biliary fistut
This case is the second and for thefirst time, it is used
for a long time in a paediatric patient with biliary
fistula.
Although it did not heal the fistula; there are
advantages for using Sandostatin; the metabolic
and skin complications of high output biliary fistula
are avoided, the patient can eat normally and
there is no need for prolonged TPN, there is no
need for a collection bag or PTC to collect the
bile as the amount is minimal and daily dressing
is sufficient; and because the drug is given subcutane-
ously hospitalization is also not needed. The
non-healing may be due to infiltration of the
tract by histocystosis-X or due to inadequate
distal drainage. The biliary enteric anastomosis-chole-
dochoduodenostomy or choledochojujenustomy-was
not performed in the 1st operation because of fear of
causing recurrent cholangitis<6) in a young child, ofthe
second attempt, it was very difficult to reach the com-
mon bile duct so cholecystojujenostomy was per-
formed but it also failed to control the fistula.
At the beginning ofthe treatment with Sandostatin,
the patient had abdominal pain which is controlled
by "Buscopan" suppositories given prior to the
Sandostatin dose. This was needed only in the first 2
weeks, no side effect were seen after prolonged use of
this a high dose, not even gallstones.
The use of Sandostatin is to be recommended in
cases of biliary fistula and there is no need to deprive
the patient of oral intake, although healing has not
been accomplished in this case, control is adequate
and healing may be accomplished in other cases.
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